Variant Bio is a Seattle-based biotech company entering a rapid growth stage having recently closed a $100mm+ Series B. The company was started because we believe that human genetics has the power to transform drug development. We are working towards developing therapies to improve global health by studying the genes of people who are outliers for medically relevant traits. To facilitate this, we have built proprietary genomics and phenotyping platforms that allow us to dramatically reduce the cost of genomic studies and identify genetically-validated targets for therapeutic development. All of our studies are co-designed with local partners: community groups, academics, and hospitals around the